Which Stock Offers Better Value: MMSI or SAUHY for Savvy Investors?

For those scouting Medical-Dental Supplies stocks, the choice between Merit Medical Systems (MMSI) and Straumann Holding AG (SAUHY) often comes down to one critical question: which represents the better value opportunity at today’s prices? Both companies operate in attractive healthcare segments, but their financial profiles tell distinctly different stories for value-conscious investors.

MMSI and SAUHY: Different Paths to Value

The investment thesis for value hunting typically rests on two pillars: identifying companies with improving analyst sentiment and spotting those trading at depressed valuations relative to their intrinsic worth. Zacks, the widely-respected equity research platform, has developed a systematic approach that combines these elements through its Rank system paired with Style Scores. This methodology has historically identified the most compelling buying opportunities.

Merit Medical currently sits at the top of this hierarchy with a Zacks Rank of #2 (Buy), signaling that analyst earnings estimates have been trending upward. Straumann, by contrast, holds a Zacks Rank of #3 (Hold), indicating more modest estimate revision activity. For MMSI investors, this upward momentum in analyst expectations provides additional confidence in the company’s trajectory.

Earnings Momentum Matters: The Zacks Rank Edge

What does the Zacks Rank really tell us? It prioritizes stocks where earnings forecasts are improving, a highly predictive signal of outperformance. When analysts begin raising guidance, it typically reflects strengthening business fundamentals—growing demand, better margins, or improved competitive positioning. MMSI’s superior ranking suggests its operational momentum has caught analyst attention in ways that extend beyond simple historical performance review.

This distinction matters because improved earnings estimates often precede stock price appreciation. By backing companies like MMSI with rising analyst confidence, value investors position themselves ahead of market recognition cycles.

Beyond Rankings: Digging Into Valuation Metrics

Yet momentum tells only part of the story. True value investors dig deeper into the actual numbers: P/E ratios, PEG ratios, Price-to-Book ratios, and cash flow metrics. These traditional yardsticks reveal which companies are genuinely trading below fair value versus merely possessing upward momentum.

MMSI trades at a forward P/E ratio of 20.07, while SAUHY commands a forward P/E of 28.57. That 40% valuation gap becomes even more pronounced when examining the PEG ratio—a metric that adjusts P/E by expected earnings growth. MMSI’s PEG of 1.95 suggests reasonable value relative to growth, whereas SAUHY’s 2.78 indicates you’re paying a significant premium for its expansion prospects.

The Price-to-Book comparison reinforces this pattern. MMSI’s P/B ratio of 3.15 reflects a moderate market premium over its book value, while SAUHY’s P/B of 8.14 suggests investors are pricing in either substantial future growth or accepting elevated valuations. For value-focused allocators, MMSI’s more conservative multiples present a more attractive entry point.

The Verdict: Why MMSI Currently Leads

When the Zacks Style Scores system evaluates companies across these valuation dimensions, MMSI earns a B grade in the Value category, marking it as genuinely undervalued. SAUHY receives a C grade, indicating weaker fundamentals from a value perspective.

This combination—superior analyst momentum through the Zacks Rank combined with actual valuation discounts reflected in MMSI’s financial metrics—makes MMSI the stronger choice for value investors surveying this space. The company demonstrates not just improving business prospects but also the rare combination of both improving analyst outlook and meaningful valuation cushion. For those building a portfolio of undervalued healthcare names, MMSI warrants serious consideration as the more compelling opportunity.